Evidence map›Paper›PMID 40880840›Full record

ArticleNature reviews. Methods primers2024

Spatial Multiplexing and Omics.

Julienne L Carstens, Santhoshi N Krishnan, Arvind Rao, Anna G Sorace, Erin H Seeley, Sammy Ferri-Borgogno, Jared K Burks

Abstract read
In one paragraph

Article in Nature reviews. Methods primers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Review
  2. Emerging technologies in the spatial proteomics landscape.Analytical and bioanalytical chemistry · 2026
    Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Cancer therapy resistance from a spatial-omics perspective.Clinical and translational medicine · 2025
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Julienne L CarstensDepartment of Medicine, Division of Hematology & Oncology, University of Alabama at Birmingham, Birmingham, AL, 35233, USA.
Santhoshi N KrishnanDepartment of Electrical and Computer Engineering, Rice University, Houston, TX, 77005, USA.
Arvind RaoDepartment of Electrical and Computer Engineering, Rice University, Houston, TX, 77005, USA.
Anna G SoraceO'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, 35233, USA.
Erin H SeeleyDepartment of Chemistry, University of Texas at Austin, Austin, TX 78712, USA.
Sammy Ferri-BorgognoDepartment of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jared K BurksDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Eric R. Fearon · 1988 to 2026
$178.2M
XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Omer Jamy · 1985 to 2026
$165.9M
Synthesizing Image-derived Heterogeneity with Genomic measurements for Assessing Disease Aggressiveness in Lower Grade GliomasR37CA214955 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KURTEK, SEBASTIAN, RAO, ARVIND · 2018 to 2024
$3.9M
Utilization of Immuno-PET to detect response and guide novel oHSV-based therapy for gliomaR01CA279143 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI JAMES M MARKERT, Anna C Sorace · 2023 to 2026
$2.3M
Personalizing immunotherapy in HER2+ breast cancer through quantitative imagingR01CA240589 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SORACE, ANNA C · 2020 to 2023
$1.6M
Mathematical modeling and molecular imaging to maximize response while minimizing toxicities from systemic therapies in preclinical models of breast cancerR01CA276540 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SORACE, ANNA C, YANKEELOV, THOMAS E · 2023 to 2025
$1.4M
NCI NIH HHS P30 CA013148NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA046592NCI NIH HHS R01 CA240589NCI NIH HHS R01 CA276540NCI NIH HHS R01 CA279143NCI NIH HHS R37 CA214955
6 · The paper itself

Abstract

Much like solving a game of Clue, understanding physiological mysteries involves answering who, what, when, and where. Multi-omics approaches delve into cellular and molecular identities (the who and what), while longitudinal data collection addresses the when. Spatial dimensions address the where. This Primer discusses current technologies enabling quantification across biological scales, emphasizing the importance of retaining the spatial dimension of that data. We outline experimental design considerations, including targeted versus untargeted approaches, sample types, biological scale, and four main classes of molecule detection. Spatial analytics are explored, covering questioning approaches, analytical platforms, image segmentation and sampling. Example applications, reproducibility considerations, limitations and our outlook for the future are provided. Our goal is to unite spatial platforms and biological scales that not commonly brought together to encourage collaboration and innovation between diverse biological fields, offering a conceptional framework and an apples-to-apples comparison for understanding major technologies to foster cross-disciplinary dialogue.

Identifiers

PMID40880840
PMCPMC12382484

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.